{
  "id": "5e31af4bfbd6abf43b00004b",
  "type": "summary",
  "question": "What is the mechanism of action of Erdafitinib?",
  "ideal_answer": "Erdafitinib is an oral selective pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/31088831",
    "http://www.ncbi.nlm.nih.gov/pubmed/31340094",
    "http://www.ncbi.nlm.nih.gov/pubmed/30021048",
    "http://www.ncbi.nlm.nih.gov/pubmed/31602692",
    "http://www.ncbi.nlm.nih.gov/pubmed/30065926",
    "http://www.ncbi.nlm.nih.gov/pubmed/28341788",
    "http://www.ncbi.nlm.nih.gov/pubmed/31770593",
    "http://www.ncbi.nlm.nih.gov/pubmed/31161538",
    "http://www.ncbi.nlm.nih.gov/pubmed/29950346",
    "http://www.ncbi.nlm.nih.gov/pubmed/31544541",
    "http://www.ncbi.nlm.nih.gov/pubmed/31673875",
    "http://www.ncbi.nlm.nih.gov/pubmed/28965185",
    "http://www.ncbi.nlm.nih.gov/pubmed/28416604"
  ],
  "snippets": [
    {
      "text": "Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28965185",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Introduction This phase 1, open-label, multicenter, single-arm, dose-escalation study aimed to evaluate safety, pharmacokinetics (PK), and pharmacodynamics of erdafitinib (JNJ-42756493), an oral selective pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, and to determine the recommended phase 2 dose in Japanese patients with advanced or refractory solid tumors. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28965185",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Findings from a phase II study indicate clinical efficacy with erdafitinib in patients with FGFR-altered inoperable or metastatic urothelial carcinoma. Robust responses were seen with this investigational pan-FGFR inhibitor, including in patients who did not respond to prior immunotherapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29950346",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In a phase 1 clinical trial, erdafitinib, a pan FGFR inhibitor, was well tolerated with a manageable toxicity profile. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30021048",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Co-cultured fibroblasts promoted SW620 and HCT116 CRC spheroid invasion, and this was prevented by the SRC and FGFR kinase inhibitors Dasatinib and Erdafitinib, respectively.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30065926",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28341788",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "JNJ-42756493, erdafitinib, is an orally active small molecule with potent tyrosine kinase inhibitory activity against all four FGFR family members and selectivity versus other highly related kinases. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28341788",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28416604",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Pathway inhibition in response to FGFR inhibitor treatment was assessed in cell lines (both in vitro and in vivo) and in samples from patients treated with the FGFR inhibitor JNJ-42756493 (erdafitinib).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28416604",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tumor cells expressing these FGFR activating mutants displayed sensitivity to the selective FGFR inhibitor erdafitinib and resulted in suppression of FGFR phosphorylation and downstream signal transduction. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28416604",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Erdafitinib, a tyrosine kinase inhibitor of FGFR1-4, has shown antitumor activity in preclinical models and in a phase 1 study involving patients with  __i_tag__ FGFR __end_i_tag__  alterations.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31340094",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Erdafitinib (Balversa\u2122, Janssen Pharmaceutical Companies) is a pan-fibroblast growth factor receptor (FGFR) inhibitor that was recently approved in the USA for the treatment of locally advanced or metastatic FGFR3 or FGFR2 urothelial carcinoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31161538",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31088831",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "JNJ-42756493 , erdafitinib , is an orally active small molecule with potent tyrosine kinase inhibitory activity against all four FGFR family members and selectivity versus other highly related kinases",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28341788",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This review covers the preclinical and clinical evidence for erdafitinib , summarizes the results of other FGFR inhibitors tested in UC and explores future perspectives of FGFR inhibition in UC",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31544541",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Erdafitinib was the first orally effective FGFR antagonist approved by the FDA (2019) for the treatment of advanced cancer, that of the urinary bladder.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31770593",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Erdafitinib, a potent oral fibroblast growth factor receptor inhibitor, is a low extraction ratio drug highly bound to alpha-1-acid glycoprotein (AGP) with free fraction (fu ) varying across populations.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31602692",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Introduction This phase 1, open-label, multicenter, single-arm, dose-escalation study aimed to evaluate safety, pharmacokinetics (PK), and pharmacodynamics of erdafitinib (JNJ-42756493), an oral selective pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, and to determine the recommended phase 2 dose in Japanese patients with advanced or refractory solid tumors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28965185",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND AND OBJECTIVES\nErdafitinib, an oral selective pan-fibroblast growth factor receptor (FGFR) kinase inhibitor, is primarily metabolized by cytochrome P450 (CYP) 2C9 and 3A4.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31673875",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Erdafitinib, a potent oral fibroblast growth factor receptor inhibitor, is a low extraction ratio drug highly bound to alpha-1-acid glycoprotein (AGP) with free fraction (fu ) varying across populations.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31602692",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Introduction This phase 1, open-label, multicenter, single-arm, dose-escalation study aimed to evaluate safety, pharmacokinetics (PK), and pharmacodynamics of erdafitinib (JNJ-42756493), an oral selective pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, and to determine the recommended phase 2 dose in Japanese patients with advanced or refractory solid tumors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28965185",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Erdafitinib, an oral selective pan-fibroblast growth factor receptor (FGFR) kinase inhibitor, is primarily metabolized by cytochrome P450 (CYP) 2C9 and 3A4.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31673875",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}